RxDoctor Payments Data

Shelton McKenzie, MD

Foot and Ankle Surgery · Washington, DCNPI 1487811808

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.9%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Linvatec Corporation at 32.6% of the total. Reporting peaked in 2023 at $8,780 and has fallen 68.0% since, to $2,805 in 2025.

$22,089in general payments, 2019–2025

Across 172 payments — averaging $128.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Linvatec Corporation$7K
  • Arthrex$3K
  • Supreme Orthopedic Systems, LLC$3K
  • Stryker$3K
  • In2bones USA, LLC$2K
  • Smith+Nephew$885
  • plus $4K from 25 others

What the payments were for

  • Consulting fees$2,0009%
  • Grants$2,50011%
  • Travel & lodging$6,49529%
  • Food & beverage$9,24642%
  • Education$1,8488%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,089 in reported general payments places this provider in the 80th percentile of 23 foot and ankle surgery providers in District of Columbia.

See all foot and ankle surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$61,375
Medicare patients
123
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium41$1,898
Naproxen19$205
Celecoxib19$156
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$113
Oxycodone Hcl16$113
Meloxicam32$106
Acetaminophen-CodeineAcetaminophen With Codeine12$79

Paid to pharmacies, not to this prescriber.

Other foot and ankle surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →